头孢哌酮舒巴坦钠联合痰热清治疗肺癌化疗后肺部感染的临床疗效

目的 分析并探讨头孢哌酮舒巴坦钠联合痰热清治疗肺癌化疗后肺部感染的临床效果.方法 选取肺癌化疗后肺部感染患者120例,采用随机数字表法分为观察组与对照组,每组60例.两组患者均给予常规的对症处理,同时给予头孢哌酮舒巴坦钠进行治疗,在此基础上,观察组联合使用痰热清注射液进行治疗.结果 观察组治疗显效34例,有效21例,无效5例,治疗有效率为91.67%,对照组治疗显效27例,有效20例,无效13例,治疗有效率为78.33%,观察组治疗有效率高于对照组,差异有统计学意义(P﹤0.05).观察组各种临床症状体征好转时间明显短于对照组,且住院时间少于对照组,差异具有统计学意义(P﹤0.05).结论 头孢哌酮舒巴坦钠联合痰热清治疗肺癌化疗后肺部感染临床效果显著,且临床症状体征好转迅速,值得推广.

The clinical efficacy of cefoperazone sulbactam combined with Tanreqing in the treatment of pulmonary infection after lung cancer chemotherapy

Objective To analyze and discuss the effect of cefoperazone sulbactam in combination with Tanreqing in the treatment of pulmonary infection after lung cancer chemotherapy. Method 120 cases of pulmonary infection devel-oped after chemotherapy were enrolled and randomized into either study group or control group, with 60 cases in each, ac-cording to a random number table. Both groups were given conventional symptomatic treatment, as well as cefoperazone sulbactam, and the study group was additionally administered with Tanreqing injection. Result For study group, there were 34 cases of partial response, 21 cases of complete response, and 5 non-responsive cases, with an effective rate of 91.67%;As for control group, there were 27 cases of partial response, 20 cases of complete response, and 13 non-respon-sive cases, and the effective rate was 78.33%, thus the overall response rate was significantly higher in the study group (P<0.05). All the clinical symptoms and signs in the study group were improved in a shorter period, besides, the hospital stay was also reduced as compared with the control group, and the differences were statistically significant (P< 0.05). Conclusion The combination therapy of cefoperazone sulbactam plus Tanreqing is clinically effective in rapidly revers-ing the symptoms of pulmonary infection after lung cancer chemotherapy, and is worthy of application.